Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells

Previous studies have shown that small-molecule BCL-2 inhibitors can have a synergistic interaction with ABCG2 substrates in chemotherapy. Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing-Quan, Li, Jonathan Y., Teng, Qiu-Xu, Lei, Zi-Ning, Ji, Ning, Cui, Qingbin, Zeng, Leli, Pan, Yihang, Yang, Dong-Hua, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072352/
https://www.ncbi.nlm.nih.gov/pubmed/32085398
http://dx.doi.org/10.3390/cancers12020466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072352/
https://www.ncbi.nlm.nih.gov/pubmed/32085398
http://dx.doi.org/10.3390/cancers12020466

Ejemplares similares